Novel effectors of ERK signaling and their potential roles in the treatment of en
ERK 信号传导的新型效应物及其在治疗 en 中的潜在作用
基本信息
- 批准号:7727351
- 负责人:
- 金额:$ 9.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-18 至 2012-08-12
- 项目状态:已结题
- 来源:
- 关键词:AccountingAntibodiesApoptosisBiological ModelsBiological Response Modifier TherapyCaenorhabditis elegansCancer BiologyCancer Cell GrowthCancer ModelCancer cell lineCell Cycle RegulationCell LineCell ProliferationCell SurvivalCellsClinicalDetectionDiagnosticDiseaseEndometrialEndometrial CarcinomaEndometriumEventFGFR2 geneHemorrhageHumanInstructionKRAS2 geneLeadMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMapsMethodsMitogen-Activated Protein KinasesMitogensModelingMolecular AbnormalityMorbidity - disease rateMutationNeoplasm MetastasisOperative Surgical ProceduresOrthologous GenePathway interactionsPatientsPharmacotherapyPhosphorylationPhosphorylation SitePhosphotransferasesPlayPopulationPostmenopausePreventionProteinsRecurrent Malignant NeoplasmReproduction sporesReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSignal Transduction PathwaySmall Interfering RNAStagingSystemic diseaseTherapeuticTherapeutic InterventionTissue MicroarrayTissuesTumor Suppressor GenesUterine CancerWestern BlottingWorkangiogenesiscarcinogenesiscell growthcell motilitychemotherapyclinically relevantcohorteffective therapyextracellularfunctional genomicsglycogen synthase kinase 3 betaimprovedmortalitymultimodalityneoplasticnovelnovel strategiesnovel therapeutic interventionsmall hairpin RNAtreatment strategytumorigenesis
项目摘要
Endometrial carinoma is the most common cancer of the female reproductive tract. Most endometrial
cancers are found at an early stage and present with postmenopausal bleeding. These patients are initially
treated with comprehensive surgical staging. This treatment is often diagnostic ofthe extent of disease and
therapeutic. However, a key clinical problem in the management of patients with uterine cancers is how to
best fre¿t~ab\r¿rhced'stagieclisease ahdlhe aggressive pathoTogic histotypes that account for signficant
mortality.
Patients with high stage or recurrent cancers have systemic disease requiring novel therapeutic
interventions. Effective therapies are largely lacking. A better understanding ofthe cancer biology, such as
signal transduction pathways, will lead to new treatment strategies that will improve the survival of these
patients. Activation of the Mitogen Activating Pathway Kinase signaling pathway contributes substantially to
endometrial tumorigenesis. Our group has identified thirty novel ERK substrates through a three-part
functional genomic approach in the C. elegans model. The human orthologs of these proteins expressed in
endometrial cancer cell lines are candidate ERK substrates. Thus far, of the candidates studied, we showed
that GSK3n is important to cell growth in multiple endometrial cancer cell lines and has potential for
therapeutic interventions.. In this proposal, we will continue to characterize novel ERK candidate substrates
in endometrial cancer. In Aim 1, we will assess expression of candidate ERK1/2 substrates in the normal
endometrium, primary endometrial cancers and endometrial cancer cell lines and determine if substrate
phosphorylation is ERK-dependent. Then in aim 2, we will determine the relationship between ERK substrate
phosphorylation status and upstream ERK signaling pathway activation in primary endometrial cancers and
clinicopathologic significance of ERK substrate expression. Finally in aim 3, we will explore GSKSD
inhibition as potential therapy for endometrial cancer and assess the role of inhibiting other ERK substrates
plays in endometrial cancer cell lines. Together these studies should provide a better understanding of the
role the ERK pathway plays in endometrial carcinogenesis and may lead to improved clinical biological
therapies.
RELEVANCE (See instructions):
The work proposed will lead to both an improved understanding of endometrial cancer biology and new
approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer
morbidity and mortality.
子宫内膜癌是女性生殖道最常见的恶性肿瘤。大多数子宫内膜
癌症是在早期发现的,并伴有绝经后出血。这些患者最初
采用综合手术分期治疗。这种治疗通常是诊断疾病的程度,
有治疗作用的然而,子宫癌患者管理的一个关键临床问题是如何
最好的早期诊断和侵袭性病理组织型,
mortality.
患有高阶段或复发性癌症的患者患有需要新治疗的全身性疾病
干预措施。有效的治疗方法在很大程度上缺乏。更好地了解癌症生物学,例如
信号转导通路,将导致新的治疗策略,将提高这些生存
患者有丝分裂原激活途径激酶信号传导途径的激活实质上有助于
子宫内膜肿瘤发生我们的小组已经通过三部分鉴定了30种新型ERK底物,
功能基因组学方法在C. elegans模型这些蛋白质的人类直向同源物表达于
子宫内膜癌细胞系是候选ERK底物。到目前为止,在研究的候选人中,我们显示
GSK 3 n对多种子宫内膜癌细胞系的细胞生长很重要,
治疗干预措施。在这项提案中,我们将继续表征新的ERK候选底物
子宫内膜癌在目标1中,我们将评估候选ERK 1/2底物在正常人中的表达。
子宫内膜、原发性子宫内膜癌和子宫内膜癌细胞系,并确定底物
磷酸化是ERK依赖性的。然后在目标2中,我们将确定ERK底物与细胞凋亡的关系。
磷酸化状态和上游ERK信号通路激活,
ERK底物表达的临床病理意义。最后,在目标3中,我们将探索GSKSD
抑制作为子宫内膜癌的潜在治疗方法并评估抑制其他ERK底物的作用
在子宫内膜癌细胞系中起作用。这些研究应能更好地了解
ERK通路在子宫内膜癌发生中的作用,并可能导致改善临床生物学特性。
治疗
相关性(参见说明):
拟议的工作将提高对子宫内膜癌生物学的了解,并带来新的
检测、预防和治疗子宫癌的方法,
发病率和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Liang Ma其他文献
Liang Ma的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Liang Ma', 18)}}的其他基金
Androgen and Wnt signaling in bladder cancer
膀胱癌中的雄激素和 Wnt 信号传导
- 批准号:
10727745 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
GENOME-WIDE IDENTIFICATION OF GENES REQUIRED FOR DECIDUALIZATION
蜕化所需基因的全基因组鉴定
- 批准号:
9258455 - 财政年份:2016
- 资助金额:
$ 9.34万 - 项目类别:
GENERATION OF AN INDUCIBLE SYSTEM IN THE UTERINE STROMA FOR IMPLANTATION STUDIES
用于植入研究的子宫间质中诱导系统的生成
- 批准号:
8358586 - 财政年份:2012
- 资助金额:
$ 9.34万 - 项目类别:
GENERATION OF AN INDUCIBLE SYSTEM IN THE UTERINE STROMA FOR IMPLANTATION STUDIES
用于植入研究的子宫间质中诱导系统的生成
- 批准号:
8522211 - 财政年份:2012
- 资助金额:
$ 9.34万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 9.34万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 9.34万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 9.34万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 9.34万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 9.34万 - 项目类别:














{{item.name}}会员




